Results 21 to 30 of about 3,454 (177)
Case Reports in Ophthalmological Medicine, 2018 We present a case of acute endophthalmitis after intravitreal dexamethasone implant injection and discuss the management of this rare and challenging case in which the implant could not be removed.
George G. Bastakis +4 more
doaj +1 more source
Dexamethasone intravitreal implant (Ozurdex) in the treatment of pediatric uveitis [PDF]
Journal of American Association for Pediatric Ophthalmology and Strabismus, 2013 To report our experience using Ozurdex (Allergan, Irvine, CA), a biodegradable intravitreal implant containing of 0.7 mg of dexamethasone approved for use in adults with noninfectious uveitis in adults, in the treatment of pediatric uveitis.The medical records of consecutive patients with noninfectious posterior uveitis who were unresponsive to ...
Monica L, Bratton +2 more
openaire +2 more sources
The Role of Steroids in the Management of Macular Edema from Retinal Vein Occlusion
Oftalʹmologiâ, 2019 Aim: To analyze the effectiveness of intravitreal injection of an anti-VEGF agent (ranibizumab) and an dexametazon implant for the intravitreal injection, in real clinical life. Patients and Methods.
M. V. Budzinskaya +4 more
doaj +1 more source
Indian Journal of Ophthalmology, 2012 We report on the significant improvement of central macular thickness in a case of clinically significant macular edema after dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex®; Allergan, Inc, Irvine, CA, USA).
Ashish Sharma +4 more
doaj +1 more source
BMC Ophthalmology, 2017 Background To quantitatively compare short-term hard exudates (HEs) alteration in patients with diabetic macular edema (DME) after intravitreal triamcinolone, dexamethasone implant or bevacizumab injections.
Yong Un Shin +5 more
doaj +1 more source
Revista Médica de Minas GeraisIntroduction: Diabetic macular edema (DME) is characterized by macular exudation and damage to retinal microvasculature. It is estimated that 30% of diabetic patients develop DME during the course of the disease.
Joice Rodrigues Rachid Amin +2 more
doaj +1 more source
Acute bacterial endophthalmitis following dexamethasone intravitreal implant: A case report
Saudi Journal of Medicine and Medical Sciences, 2019 A 54-year-old male presented to our ophthalmology clinic with a diagnosis of the right central retinal vein occlusion with macular edema. The patient was treated with dexamethasone intravitreal implant. Three days after the implant insertion, the patient
Waseem Al Zamil, Sanaa A Yassin
doaj +1 more source
Dexamethasone intravitreal implant in the crystalline lens: a case report
Arquivos Brasileiros de Oftalmologia, 2020 This report describes the therapeutic effects and outcomes of an accidental injection of an intralenticular sustained-release dexamethasone implant (Ozurdex®) in three patients with diabetic macular edema. All three patients underwent accidental injections of sustained-release intravitreal dexamethasone implants into the crystalline lens by the same ...
Ertan, Elif +3 more
openaire +3 more sources
Case Reports in Ophthalmology, 2023 Dexamethasone intravitreal implant (Ozurdex®; Allergan, Inc., CA, USA) has been proved to be effective in a variety of clinical settings including cases of pseudophakic cystoid macular edema.
Panagiotis Stavrakas +5 more
doaj +1 more source
Budget impact analysis of dexamethasone intravitreal implant for the treatment of diabetic macular oedema [PDF]
Farmacia Hospitalaria, 2018 : Objective: To assess the economic impact following the inclusion of an intravitreal implant of dexamethasone for the treatment of diabetic macular oedema in a healthcare area in Spain.
Fernando de Andrés-Nogales +5 more
doaj +1 more source